-
Thematic Analysis
NewDigital Twins – Thematic Intelligence
Digital Twins Thematic Report Overview Digital twins are digital representations of physical assets, systems, people, or processes. They help in detecting, preventing, predicting, and optimizing the physical environment using artificial intelligence (AI), real-time analytics, visualization, and simulation tools. Digital twins can provide short and long-term efficiency and productivity gains by dynamically integrating data and information about an asset, part, process, or system’s lifecycle. They are a data resource that can improve asset design, understand an existing asset’s condition, verify the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Leptomeningeal...
-
Product Insights
Rosacea – Drugs In Development, 2023
Global Markets Direct’s, ‘Rosacea - Drugs In Development, 2023’, provides an overview of the Rosacea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dermatological Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatological Disorders - Drugs In Development, 2023’, provides an overview of the Dermatological Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatological Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vitiligo – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitiligo - Drugs In Development, 2023’, provides an overview of the Vitiligo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Gouty Arthritis (Gout) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Drugs In Development, 2023’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Musculoskeletal Inflammation – Drugs In Development, 2023
Global Markets Direct’s, ‘Musculoskeletal Inflammation - Drugs In Development, 2023’, provides an overview of the Musculoskeletal Inflammation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Musculoskeletal Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rebonuputemcel in Degenerative Disc Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Rebonuputemcel in Degenerative Disc DiseaseDrug Details:Rebonuputemcel is under development for the treatment of lumber, cervical, adjacent...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M and A In Pharmaceutical Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract...